KG
CORT icon

Kilter Group’s Corcept Therapeutics CORT Stock Holding History

Kilter Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348 Buy
+4
New +$242 ﹤0.01% 1431
2026
Q1 		– Sell
-23
Closed -$801 – 1601
2025
Q4 		$801 Hold
23
– – ﹤0.01% 1115
2025
Q3 		$1.91K Hold
23
– – ﹤0.01% 679
2025
Q2 		$1.69K Buy
+23
New +$1.67K ﹤0.01% 669

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kilter Group's CORT Position: Q2 2026 in Review

Kilter Group opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 4 shares worth $348. The stake represents ﹤0.01% of the portfolio and ranks #1431 among its holdings. This is a return to the name: Kilter Group previously reported a position in CORT as recently as Q4 2025.

Kilter Group first reported a position in CORT in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.91K in Q3 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Kilter Group held 4 shares of Corcept Therapeutics worth $348 as of Q2 2026.
  • Corcept Therapeutics was a new Kilter Group position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #1431 holding.
  • Kilter Group first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Kilter Group's Corcept Therapeutics position peaked at $1.91K in Q3 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.